Importantly, our assay has been verified for HER2 biomarker quantification on the serum samples from breast cancer patients with the receptor status labeled as low (HER2 (1+) and HER2 (2+)/FISH negative). The gene discussed is ERBB2; the disease is breast carcinoma.